Related Experiment Video
Updated: May 11, 2026

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
Published on: December 30, 2016
Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against
Taofeng Du1, Yasuhiro Nagai, Yan Xiao
1Department of Pathology and Lab Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104-6082, USA.
Abstract:
p300 is one of several acetyltransferases that regulate FOXP3 acetylation and functions. Our recent studies have defined a complex set of histone acetyltransferase interactions which can lead to enhanced or repressed changes in FOXP3 function. We have explored the use of a natural p300 inhibitor, Garcinol, as a tool to understand mechanisms by which p300 regulates FOXP3 acetylation. In the presence of Garcinol, p300 appears to become disassociated from the FOXP3 complex and undergoes lysosome-dependent degradation. As a consequence of p300's physical absence, FOXP3 becomes less acetylated and eventually degraded, a process that cannot be rescued by the proteasome inhibitor MG132. p300 plays a complex role in FOXP3 acetylation, as it could also acetylate a subset of four Lys residues that repressively regulate total FOXP3 acetylation. Garcinol acts as a degradation device to reduce the suppressive activity of regulatory T cells (Treg) and to enhance the in vivo anti-tumor activity of a targeted therapeutic anti-p185(her2/neu) (ERBB2) antibody in MMTV-neu transgenics implanted with neu transformed breast tumor cells. Our studies provide the rationale for molecules that disrupt p300 stability to limit Treg functions in targeted therapies for cancers.
Insights
Garcinol, a p300 inhibitor, causes p300 degradation, reducing regulatory T cell (Treg) function. This enhances anti-tumor antibody efficacy, suggesting p300 stability disruption for cancer therapy.
Area of Science:
- Molecular Biology
- Immunology
- Cancer Research
Background:
- p300 is a key regulator of FOXP3 acetylation and function.
- Histone acetyltransferase interactions influence FOXP3 activity.
- Understanding p300's role in FOXP3 regulation is crucial for cancer therapy.
Purpose of the Study:
- To investigate the mechanism by which p300 regulates FOXP3 acetylation.
- To explore the use of the natural p300 inhibitor, Garcinol, as a tool.
- To assess the therapeutic potential of targeting p300 stability in cancer.
Main Methods:
- Utilized Garcinol to study p300-FOXP3 interactions.
- Investigated p300 degradation pathways (lysosome-dependent).
- Assessed FOXP3 acetylation and degradation.
- Evaluated the effect of Garcinol on regulatory T cell (Treg) function and anti-tumor activity in MMTV-neu transgenic models.
Main Results:
- Garcinol induces p300 dissociation from FOXP3, leading to lysosome-dependent degradation.
- p300 degradation results in decreased FOXP3 acetylation and subsequent degradation, independent of proteasomal activity.
- Garcinol reduces Treg suppressive activity.
- Garcinol enhances the in vivo anti-tumor efficacy of an anti-HER2 antibody.
Conclusions:
- p300 plays a dual role in FOXP3 acetylation, with some sites repressing overall acetylation.
- Garcinol effectively disrupts p300 stability, reducing Treg function.
- Targeting p300 stability offers a promising strategy to limit Treg activity and enhance anti-tumor therapies in cancer.
Related Concept Videos
Abnormal Proliferation
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
